verenafusp alfa (GNR-055)
/ Generium
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
July 31, 2025
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
(clinicaltrials.gov)
- P2/3 | N=32 | Recruiting | Sponsor: AO GENERIUM | Trial primary completion date: Feb 2025 ➔ Jun 2026
Trial primary completion date • Hunter Syndrome • Metabolic Disorders
June 26, 2024
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=18 | Completed | Sponsor: AO GENERIUM
New P1 trial • Hunter Syndrome • Metabolic Disorders
February 23, 2023
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
(clinicaltrials.gov)
- P2/3 | N=32 | Recruiting | Sponsor: AO GENERIUM | Trial completion date: Mar 2025 ➔ Mar 2028
Trial completion date • Hunter Syndrome • Metabolic Disorders
January 26, 2022
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
(clinicaltrials.gov)
- P2/3; N=32; Recruiting; Sponsor: AO GENERIUM
New P2/3 trial • Hunter Syndrome • Metabolic Disorders • MRI
October 14, 2020
A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
(clinicaltrials.gov)
- P1; N=20; Completed; Sponsor: AO GENERIUM; Recruiting ➔ Completed
Clinical • Trial completion • Hunter Syndrome • Metabolic Disorders
September 08, 2020
A Multi-cohort Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
(clinicaltrials.gov)
- P1; N=20; Recruiting; Sponsor: AO GENERIUM
Clinical • New P1 trial • Hunter Syndrome • Metabolic Disorders
1 to 6
Of
6
Go to page
1